Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipent, Cytoxan, and Rituxan in CLL
NCT00131313Phase 4Unknown
- Sponsor
- East Valley Hematology and Oncology
- Start
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclophosphamide in chronic lymphocytic leukemia (CLL), sponsored by East Valley Hematology and Oncology. Primary endpoint: Efficacy response rate. Status: unknown.
02
Drugs
cyclophosphamide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00131313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131313.